Close Menu

A molecular profiling platform for childhood cancer that combines germline and tumor whole-genome sequencing (WGS), RNA sequencing (RNAseq), and central nervous system methylome analysis is reported in this week's Nature Medicine. In the study, members of Australia's Zero Childhood Cancer Program apply the approach to 252 tumors from high-risk pediatric cancer patients, identifying a range of germline and somatic driver variants and contributing significantly to treatment recommendations.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.